Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens (NASDAQ:VKTX)
Viking TherapeuticsViking Therapeutics(US:VKTX) Seeking Alpha·2026-02-12 05:44

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]